All In Biotech

Drug Trial Radar · NCT01176266

Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)

An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase Alfa (Human Recombinant Tissue-nonspecific Alkaline Phosphatase Fusion Protein) in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)

Last checked: Nov 20, 2026Latest source record: Mar 13, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

69

Actual

Start

Jul 2010

Primary completion

Sep 2016

Study completion Sep 2016

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 5, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 minute, up to 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial was conducted to study hypophosphatasia (HPP), a bone disorder caused by gene mutations or changes. These gene mutations cause low levels of an enzyme needed to harden bone. The purpose of this study was to test the safety and efficacy of a study drug called asfotase alfa (human recombinant tissue non-specific alkaline phosphate fusion protein) to see what effects it has on patients 5 years of age or less with HPP.

Conditions

  • Hypophosphatasia

Interventions

  • asfotase alfaDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effect of Asfotase Alfa Treatment on Skeletal Manifestations of Hypophosphatasia (HPP)Time frame: From Baseline to Week 24
  2. Safety and Tolerability of Repeated Subcutaneous (SC) Injections of Asfotase AlfaTime frame: Up to 72 months or until regulatory approval in the country of residence. Patients received study drug for a median duration of 829.0 days, with a range from 6 to 2116 days (ie, from 0.9 week to 5.8 years).

Locations

23 sites in 12 countries. Site status is shown where the registry gives one.

  • Children's Hospital & Research Center Oakland

    Oakland, California

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Children's Hospital of Pittsburgh of UPMC

    Pittsburgh, Pennsylvania

  • Lady Cilento Children's Hospital

    South Brisbane, Queensland, Australia

  • Royal Children'S Hospital Melbourne

    Parkville, Victoria, Australia

  • Health Sciences Centre Winnipeg, University of Manitoba

    Winnipeg, Manitoba, Canada

  • Necker Hospital

    Paris, France

  • Chu de Toulouse

    Toulouse, France

  • Universitätskinderklinikum Würzburg

    Würzburg, Germany

  • Istituto Giannina Gaslini

    Genova, Italy

  • Ospedale Pediatrico Bambino Gesù

    Roma, Italy

  • Saitama Municipal Hospital

    Saitama, Japan

  • Fukuoka Higashi Medical Hospital

    Koga, Fukuoka, Japan

  • Ishikawa Prefectural Hospital

    Kanazawa, Ishikawa-ken, Japan

  • St. Marianna University School of Medicine, Yokohayama City Seibu Hospital

    Yokohama, Kanagawa, Japan

  • Tokyo Medical University Hospital

    Shinjuku, Tokyo, Japan

  • Federal State Budgetary Institution

    Moscow, Russia

  • King Faisal Specialist Hospital and Research Center

    Riyadh, Saudi Arabia

  • Hospital Infantil Universitario Nino Jesus

    Madrid, Spain

  • Uludag University

    Bursa, Turkey (Türkiye)

  • Birmingham Children's Hospital

    Birmingham, United Kingdom

  • Royal Manchester Children'S Hospital

    Manchester, United Kingdom

  • Sheffield Children'S Hospital

    Sheffield, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.